Updates from the European Glaucoma Society Meeting 2022
I have just returned from the European Glaucoma Society Meeting held in Athens. This is a biannual glaucoma meeting and one of the largest glaucoma meetings worldwide. One of the highlights of the scientific programme was around neuroprotection and in particular, potential new agents that may help to protect the optic nerve from glaucoma damage, such as Nicotinamide (vitamin B3). Glaucoma’s main risk factor is eye pressure and the focus of treatment does remain on lowering the eye pressure either through glaucoma drops, glaucoma laser or glaucoma surgery, but certainly looking at other mechanisms of protecting the optic nerve is very exciting.
Personally, I was involved in ongoing work and I was delighted to present research demonstrating an improvement in Quality of Life and Ocular Surface Comfort after Glaucoma Surgery. We also presented our work looking at artificial intelligence and helping clinicians make the best decisions for glaucoma treatments. This is particularly important as nowadays there are many more treatment options for glaucoma and it is important when deciding on the most appropriate treatment that this is based on the full clinical picture and scientific outcomes from multiple surgeons.
Do feel free to share our newsletter with friends and family to continue to raise awareness about eye health.